Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Itepekimab in Chronic Rhinosinusitis Without Nasal Polyps
NCT06691113Phase 2Completed
- Sponsor
- Sanofi
- Start
- Dec 2024
- Primary completion
- Mar 2026
- Modality
- Monoclonal Antibodies
- Countries
- 13
01
Overview
Phase 2, randomised, double-blind trial of itepekimab in chronic rhinosinusitis without nasal polyps (CRSsNP) (3 arms), sponsored by Sanofi. Primary endpoint: Change from baseline in sinus (maxillary, ethmoid) percent opacification volume assessed by CT scan at 24 weeks. Started Dec 2024; status: completed.
02
Drugs
itepekimab
03
Conditions
chronic rhinosinusitis without nasal polyps (CRSsNP)
Beyond the preview
Go deeper on NCT06691113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06691113.